Spencer Feldman

Trials enrolling patients with relapsed leukemia, lymphoma and brain cancers, respectively, report early data showing safety/activity with novel therapies.

FDA approves updated labeling for Talzenna plus Xtandi in men with HRR gene-mutated metastatic prostate cancer, showing a 14-month survival benefit.

The FDA approved Monjuvi with Revlimid and Rituxan for R/R follicular lymphoma after it showed significantly longer progression-free survival vs placebo.

Atebimetinib with modified chemo led to 94% 6-month survival rates in first-line pancreatic cancer, with durable responses and a favorable safety profile.

Breyanzi demonstrated a 95.5% response rate among patients with relapsed/refractory marginal zone lymphoma, as well as a durable safety.

The FDA granted fast track designation to nuvisertib for those with intermediate or high-risk myelofibrosis, which demonstrated symptom relief in patients.

Surgery and radiation yield similar cancer outcomes for low-risk prostate cancer, but higher-risk cases may require combining treatments, experts said.

The FDA granted fast track designation to RAD101, an experimental imaging agent, to improve detection of recurrent brain metastases.

Keytruda was approved for locally advanced head and neck cancer before and after surgery, showing improved event-free survival versus standard care.

FDA approves new Brukinsa tablet for five blood cancers, offering simpler dosing with the same safety and effectiveness as capsules.

The U.S. FDA has approved treatment with Ibtrozi for patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer.

FDA granted priority review to Zepzelca plus Tecentriq for first-line maintenance in extensive-stage small cell lung cancer.

The FDA grants fast track designation to PHST001, an antibody targeting CD24, for advanced platinum-resistant and platinum-sensitive ovarian cancer.

The first patient has been dosed in the phase 3 TERZO trial of Copiktra for relapsed or refractory nodal T-follicular helper cell lymphoma.

The FDA granted orphan drug designation to MVdeltaC, a measles virus-based immunotherapy, for pleural mesothelioma, supporting its future development.

Patients with oligometastatic lung cancer may live longer with surgery, but experts stress the need for multidisciplinary evaluation to guide treatment choices.

Iopofosine-131 received FDA breakthrough status for relapsed or refractory Waldenstrom macroglobulinemia, showing strong response rates in early trials.

Higher radiation doses in lung cancer treatment carry no added risk of inflammation and may improve survival.

Rina-S led to a 50% response rate, including two complete responses, in heavily pretreated advanced endometrial cancer, according to early trial findings.

The FDA approved Nubeqa for metastatic castration-sensitive prostate cancer based on significantly improved radiographic progression-free survival data.

Blocking serotonin transporters with antidepressants boosted CD8 T cell function and enhanced immunotherapy response in mouse and human tumor models.

The FDA has accepted and granted priority review to an NDA for sevabertinib in previously treated HER2+ non-small cell lung cancer.

Neoadjuvant efti and Keytruda plus radiotherapy met the EFTISARC-NEO trial's primary end point by improving tumor fibrosis in soft tissue sarcoma.

Radiation therapy can treat lung cancer at all stages, easing symptoms, improving precision and minimizing side effects with modern techniques.

The first patient has received treatment with mavrostobart plus chemo in the phase 1/2 MORNINGSTAR trial for advanced solid tumors, including lung cancer.

A patient with relapsed follicular lymphoma achieved complete remission one month after PMB-CT01 treatment in the phase 1 PMB-102 trial.

DPOAE testing showed no hearing loss in children with retinoblastoma treated with intra-arterial paraplatin, suggesting preserved cochlear function.

ZL-1310 earns fast track designation in extensive-stage small cell lung cancer after early trial data showed tumor shrinkage in most patients treated.

Tumors shrank more with the addition of acoustic cluster therapy to chemotherapy in colorectal liver metastases in the phase 1 ACTIVATE trial.

Younger patients with lung cancer are more likely to have mutations that allow for targeted therapies, which can lead to more personalized and effective treatment.